// App-Quantinova.ai

: The global, prospective, observational PARADIGHM™ registry for patients with chronic hypoparathyroidism was expanded to capture recombinant human parathyroid hormone, rhPTH(1-84), use under routine clinical care

Researchers

Presenter

  • Bart L Clarke

Principal Investigators

  • Lars Rejnmark

  • Maria Luisa Brandi

  • John Germak

  • Stefanie Hahner

  • Pascal Houillier

  • Olle Kampe

  • Christian Kasperk

  • Aliya Khan

  • Michael A Levine

  • Michael Mannstadt

  • Rebecca Piccolo

  • Dolores M Shoback

  • Tamara J Vokes

  • Neil Gittoes

Medical Centers

  • Mayo Clinic, Rochester, Minnesota

  • Aarhus University Hospital, Aarhus, Denmark

  • University Hospital Careggi, Firenze, Italy

  • Shire International GmbH, Zug, Switzerland

  • University of Wurzburg, Wurzburg, Germany

  • Georges Pompidou European Hospital, Paris Descartes University, Paris, France.

  • Karolinska Institutet, Stockholm, Sweden

  • Heidelberg Medical University, Heidelberg, Germany

  • McMaster University, Hamilton, ON, Canada

  • The Childrenaaas Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

  • Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, United States

  • Shire Human Genetic Therapies, Inc., Lexington, Massachusetts, USA

  • SF Department of Veterans Affairs Medical Center, University of California, San Francisco, California, USA

  • University of Chicago Medicine, Chicago, Illinois, USA

  • University of Birmingham, Birmingham, United Kingdom

Locations

  • United States

  • Denmark

  • Italy

  • Switzerland

  • Germany

  • France

  • Sweden

  • Canada

  • United Kingdom

Companies

  • Shire

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • N/A

Biomarkers

  • Parathyroid Hormone

Drug/Treatment

  • rhPTH

  • Recombinant Human Parathyroid Hormone (1-84)

  • Teriparatide

  • Ergocalciferol

Outcome

  • N/A

Study Design

  • Observational

  • Prospective

Phase

  • NA

Study Id's

  • NCT01922440

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved